Hot Features
Premium
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Etf Name | Etf Symbol | Market | Stock Type |
|---|---|---|---|
| Strategic Trust Kelly CRISPR and Gene Editing Technology ETF | XDNA | NASDAQ | Exchange Traded Fund |
| Price Change | Price Change % | Etf Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 7.38 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 7.38 |
| Trades | Etfs Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 5.87 - 9.8099 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | 7.38 | USD |
Strategic Trust Kelly CRISPR and Gene Editing Technology ETF Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 2.58M | - | - | - | 25.51 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
News Strategic Trust Kelly CR...
Real-Time news about Strategic Trust Kelly CRISPR and Gene Editing Technology ETF (NASDAQ): 0 recent articles
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
XDNA Historical
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Year | 9.38 | 9.8099 | 5.87 | 7.88 | 3,541 | -2.00 | -21.32% |
| 3 Years | 14.76 | 14.99 | 5.87 | 11.17 | 4,421 | -7.38 | -50.00% |
| 5 Years | 14.76 | 14.99 | 5.87 | 11.17 | 4,421 | -7.38 | -50.00% |
| The Kelly CRISPR & Gene Editing Technology ETF (the Fund) seeks to track the total return performance, before fees and expenses, of the Strategic CRISPR & Gene Editing Technology Index (the Index). The Fund employs a passive management (or indexing) investment approach designed to track the total return performance, before fees and expenses, of the Index. The Index is based on a proprietary methodology developed and maintained by Strategic Indexes, LLC (the Index Provider), an affiliate of Kelly Strategic Management, LLC, the Funds investment adviser (the Adviser). Unlike many investment companies, the Fund does not try to beat the Index and does not seek temporary defensive positions when markets decline or appear overvalued other than those indicated in the Index. |
